Book / livre en 2 langues français and English

English links:

Finally we did My Book publication in English:

Marc The Invicible: A true story of my son’s resurrection from cardiac arrest followed by anoxic brain damage


Kindle format:

Paper book:


Voilà mon livre : en 2 possible versions « Marc L’invincible » ( en français)


en livre broché sur Amazon:

The live chat 31 July about the clinical trials, future research, and treatments with cord blood in Russia

Link to lisen interview

Dr. Olga Tyumina is the President of Ruscord, a non-profit organization of specialists and organizations in the field of procurement, storage and use of umbilical cord blood and cellular technologies. Dr. Tyumina is a prominent doctor in medical sciences, professor of the Russian Academy of Sciences, honored health worker in the Samara Region (Russia), and the Director of the Samara Regional Medical Center, Dynasty. She is the author of 120 publications and holds multiple patents, registered computer programs and monographs.

Dr. Stanislav Volchkov is the Deputy Director of the Samara Regional Medical Center, Dynasty, the Executive Director of the non-profit Hematopoietic Progenitor Cells Registry, Expert of the Fund for Assistance to Small Innovative Enterprises in Science and Technology, Founder of the Institute of Biotechnology and Pharmacology Inbiopharma, LLC, and is a certified designee for biomedical cellular products acquired by Ministry of Health of the Russian Federation.

In this live chat we will discuss the clinical trials, future research, and treatments currently provided at the Center of Cellular Technologies in Samara (Russia) using donor cord-blood transfusions and other stem cell therapies for the treatment of Autism, Cerebral Palsy and other developmental disorders.

Galileo et Alinker

Galileo : Galileo | Side Alternating Vibration

Dernière étude 2019: The immediate influence of various whole-body vibration frequency on balance and walking ability in children with cerebral palsy: a pilot study:

Worth Knowing – Kids

Autres études ( il y a beaucoup)

« Le WBVT fourni par Galileo plate est caractérisé par des mouvements de bascule qui stimulent un modèle de mouvement similaire à la démarche humaine. Celles-ci entraînent l’activation de circuits vertébraux propriétaires-réceptifs, conduisant ainsi à des contractions musculaires rythmiques compensatoires dans les membres inférieurs et le tronc. Nos participants ont non seulement affiché des améliorations de la masse musculaire, mais également des améliorations de la teneur en minéraux osseux et de la densité allant de 1 à 5%. L’augmentation de la masse osseuse était probablement due à l’effet de l’action musculaire sur l’os pendant le WBVT, combiné aux effets de l’amélioration de la mobilité observée. Ainsi, nos résultats cadrent bien avec la théorie du mécanostat, dans laquelle la charge mécanique (dans ce cas, les contractions musculaires générées par la plate-forme de vibration et l’amélioration de la mobilité) a entraîné des effets positifs sur les os, tels qu’une augmentation de la masse osseuse. Notez que nos résultats étaient similaires à ceux observés par Stark et al. après 6 mois de thérapie combinée dans un groupe de 78 enfants atteints de GMFCS I à V, qui ont rapporté respectivement une augmentation de 2,3% et 5,7% de la densité et de la teneur totale en minéraux osseux. Cependant, leur intervention impliquait non seulement le WBVT, mais aussi d’autres formes de physiothérapie, de musculation et d’entraînement sur tapis roulant, ce qui rendait impossible l’identification des effets spécifiques du WBVT. Néanmoins, Wren et al. ont examiné l’impact de l’entraînement quotidien aux vibrations seul sur la santé osseuse des enfants atteints de PC âgés de 6 à 12 ans, observant des améliorations de la zone osseuse corticale par rapport à un régime de simplement se tenir debout sur le sol8.

Alinker: ( vélo – debout) pour marcher ( Marc manque encore 2 cm longueur des jambes)

Duke study for ASD children’s with allogenic and autologous cord blood

Interview : by Enrique Basurto :

Link to lisen:

Key takeaways from our live interview with Dr. Joanne Kurtzberg today re. the results of the phase-II trial using cord-blood infusions in children with Autism,

1. As noted in the Discussion section of the publication, the research Team believes that the lower than needed sample of children with non-verbal IQ > 70 might have compromised the results of the study. However, although the study did not meet the target outcome (as measured by the Vineland socialization scale), there were statistically significant improvements in the higher non-verbal IQ (NVIQ) cohorts particularly in 4-to-7 y.o. in communication scales, eye tracking and EEG

2. Currently, there are 3 stem cell studies for Autism where the Duke Team is involved: a) Using cord tissue MSCs (where 500-1,000 doses could be extracted from a single cord and therefore multiple infusions could be received) with 4-to-7 year olds with NVIQ > 70 (with NVIQ measured at Duke as opposed to remotely in order to -hopefully- ensure statistical significance next time). b) A study in China aiming at diagnosing and treating Autism using cord-tissue infusions earlier in life. c) A small trial with ASD adults ages 18 to 35. These 3 trials are already funded but currently on hold due to COVID-19 but are expected to resume ASAP. Dr. Kurtzberg noted that in the future, it is possible that a combination of multiple stem cell sources could show higher efficacy than any individual source could achieve on its own, e.g. starting with a cord-blood infusion followed by cord-tissue MSCs infusions every 3-6 months to sustain benefits

3. In order to get FDA-approval for cord-blood infusions in the US, it is necessary to show definite benefit in a phase-III randomized placebo controlled trial. To that effect, the Duke Team believes that the results from the phase-II trial are compelling enough to seek funding for a phase-III trial with cord blood infusions in 4-to-7 year olds with NVIQ > 70. (As a side note, limiting the sample to 4-7 y.o. with NVIQ > 70 does not mean that lower functioning children could not benefit from cord-blood infusions, that is simply to delineate the inclusion criteria that is most likely to demonstrate benefits in the shortest amount of time)

4. During the course of the phase-II trial, the vast majority of parents who « guessed » when their children had received the cord-blood infusion (as opposed to the placebo) based on the improvements they observed in behaviors, focus, concentration, socialization, testing and communication (by ether increasing their vocabulary or by appropriately using the words they had) were correct. OTOH, The placebo effect was reportedly higher than expected, part of the reason why this could have happened was due to the tools used to assess improvements in 2-to-4 year olds, specially given the fact that this is an age where children in general could potentially acquire various skills

5. In principle, it is possible to get FDA-approval for an expanded access program using donor cord-blood infusions for children with Autism. However, the waiting list for the autologous infusions already surpasses the capacity of the Team at Duke. That said, Duke is currently working with a few other clinics/centers/hospitals to open up expanded access programs around the US (e.g. MD Anderson, Rutgers, etc.) that can provide access to cord-blood infusions without the long waiting lists

6. Although MSCs can be manufactured from adipose tissue or from the bone marrow, based on several studies, Dr. Kurtzberg believes MSCs from umbilical cord tissue are more potent. That said, studies using MSCs using bone marrow have also shown positive outcomes in Autism. Dr. Kurtzberg mentioned exosomes are controversial and have not been studied as much as MSCs. MSCs activate macrophages so the use of exosomes without MSCs may not cause the kind of benefits compared to when MSCs are present

7. Regarding prep work, the research Team has not found any indication that diets, supplements or other biomedical treatments can increase that chance of success from stem cell therapy

8. In theory, infusing HLA-matched (or partially HLA-matched) cord-blood in a recipient should increase the amount of time that the donor cells can survive in the recipient’s body. Also, by infusing HLA-matched cord blood there is less chance of « sensitizing » the recipient’s system against foreign HLA which could potentially make the recipient develop antibodies that could limit the donor base later in life if transfusions were needed for other reasons

Publication ->

#AutismIsMedical #AutismIsTreatable #1in54 #FlattenTheAutismCurve #AutismPandemic #TheRealPandemic

« In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale”

And: “Children without ID treated with CB showed significant improvements in communication skills (VABS-3 Communication Domain), and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power.”

“The rationale is that CB CD14+ monocytes act through paracrine signaling to modulate brain inflammation and/or immune abnormalities, improving brain function and behavior.”

“One hundred eighty children, aged 2-7 years (mean ± SD, 5.47 ± 1.65) who met DSM-5 criteria for ASD participated. Diagnosis was based on the Autism Diagnostic Observation Schedule-217 and Autism Diagnostic Interview, Revised.18 Participants were screened for a genetic cause of ASD with testing for Fragile X and chromosomal microarray. Inclusion criteria included (1) negative genetic testing, (2) qualified CB unit with a minimum banked total nucleated cell dose of ≥2.5 × 107 cells/kg or ≥4/6 HLA-matched allogeneic unrelated CB unit, (3) stable on medications for ≥2 months, (4) ability to travel to study site twice, (5) English speaking, and (6) normal absolute lymphocyte count (≥1500/μL).”

But : “Infused dose was not associated with the primary and secondary outcomes, with the exception of the CGI. The allogeneic cohort received a higher TNC dose compared with the autologous cohort (3.8 × 107/kg vs 2.7 × 107/kg) making it impossible to determine whether the effect in the allogeneic group was due to the higher cell dose or to CB type.”

“When participants with NVIQ ≥70 were analyzed separately, the results indicated that participants without ID who were treated with CB exhibited significantly increased relative alpha powerposterior/toys (P = .02) and significantly increased relative beta1 powerall brain regions/social (P = .02) compared with the placebo group (Figure 5). No main effects were found for theta or gamma power.”

“However, for children without ID, clinician CGI ratings indicated that children treated with allogeneic CB, but not those treated with autologous CB, showed improvement over placebo. Children without ID also showed significantly greater improvement in a prespecified secondary outcome measure of VABS Communication SS when treated with CB compared with placebo.”

EXO serum or haw I found best cream for me while studying cord blood ….

Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulates rejuvenation of human skin!!!!

And :

Denise Serigny my mother in law send me her testimonial for EXO: (she does not have Facebook now) and she is 78 years old!

But this is her experience after 6 months:

“What a pleasure to put on my face, morning and evening, this little drop of EXO.

Immediately i felt my skin becomes “full” of this elixir and in a few seconds nourishes and beautifies it.

I always thought, that i will become “old » in natural way… I would never resort to cosmetic surgery, I want to keep on my face the traces of my history.

EXO, suits me fully : gradually reducing fine wrinkles and slightly filling the skin , giving it a « healthy glow » effect.”

Description EXO :–OoUmNIMMub0aAzZp2pYPue05NQsdrU0cEdHQfuBPzHTspduQb5KtCVEefB6OOPLoMtKEE8kXRMaLt3NtgjreeZe

A lot of friends ask me how to maintain youth and look good at my age (I’m 46 on the left of photo) …so ….honestly, I think several factors play a role …

Of course genetics; nutrition and physical activity … but for the skin …. not only …. my friends often ask me what cream I use …. I honestly did not use any;) before….but recently we drove to treat our son brain injury in Samara and there I found a cream on a natural basis – based on exosomes ….from umbilical cord blood .. (I studed a lot of scientific literature on umbilical cord blood as you can find in previous articles on my blog….for my son and therefore I know a lot about its capabilities) therefore it was this serum with exosomes that I personally was interested to give a try and honestly the result on my face became already visible after 2 months!

I can testify that after 8 months of treatment an excellent result on my face skin really great some wrinkles are less visible (but the result is absolutely natural) not like the stretched and inflated faces of Botox stars …oh … the horror … 😂

I am 46 years old, and I am very pleased with EXO serum, it is effective, soft and natural – and, in my opinion, it is ideal (I am not a supporter of Botulique toxins and not a supporter of plastic surgeries – I consider this exagération – in pursuit of “rejuvenation” and results …. haw to say – better to use in horror films- very unnatural and doubtful …. and it could harm your health ! Botox can harm you it’s toxic…..

Of cause at the same time, as any woman I’m looking for a way to stay attractive – but as “natural” as possible and therefore I personally really like EXO Serum.

It should be noted that this is not just external beauty, but also real skin health and restoration of skin functions! So very very healthy !!!!

Exosomes of umbilical cord mesenchymal cells have proven effective for skin rejuvenation in preclinical studies by a group of scientists from the USA and China. Experiments have shown that exosomes can potentially be used to regenerate and rejuvenate the skin with various defects. The work was published in ACS Omega magazine:

Exosomes have the ability to stimulate the proliferation of dermal fibroblasts, as well as enhance their production of collagen, elastin and fibronectin.

As I wrote earlier, EXO underwent research in Samara for burns and healing wounds.

Everything was perfectly explained long ago in the video:

I buy my face EXO serum in Russia! I live in france but I prefer this serum than any other big French marks of face creams and serums….


You want to see files find more videos and about see on fb page:

So Israël will start randomized HBOT trail for COVID19 ?

So here study in Israel will start soon:

The purpose of Israel’s study is to evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.

This Swiss study and also some studies in USA ( with hbot) still makes me think that hbot may be good therapie for COVID19 patients :

I will explain 

Hère Swiss last study: ( published in Lancet)

This is new interesting study:

« The endothelial tissue of younger patients is usually capable of coping well with the attacks launched by the virus. The situation is different for patients suffering from hypertension, diabetes, heart failure or coronary heart diseases, all of which have one thing in common – their endothelial function is markedly impaired. If patients such as these become infected with SARS-COV-2, they will be particularly at risk, as their already weakened endothelial function will diminish even further, especially during the phase in which the virus reproduces the most.  « 


Link to Swiss article :

So in fact they talk about :

Endothelial dysfunction  And capacity to produce nitric oxide (NO)….

And we have a lot of studies ( with hbot) One of them Shai study:

« In a study on rats with normal mitochondrial function, HBOT increased the production of adenosine triphosphate in muscle tissue compared to a control group [29]. Moreover, in a clinical study by Li et al., it was demonstrated that HBOT may improve myocardial blood perfusion, reduce inflammation and vascular endothelial dysfunction, and further improve myocardial microcirculation in patients after the implantation of drug-eluting stents [30]. Aparci et al. evaluated the changes following a series of 10 hyperbaric sessions in diabetic patients [31] »

So if  HBOT improve myocardial blood perfusion, reduce inflammation and vascular endothelial dysfunction we are searching improve level of NO ( in all types cardiac patients) so I think for such category of patients may be hbot could be used even before any COVID19 infection ?.. ( may be than if their capacity to produce nitric oxide (NO)will be normalise or almost) we will see much more less cardiac person with bad Covid 19 outcome ????

This study as well….

why Professor Raoult’s protocol is not tested stricto sensu in the Discovery trial?

I would like to know why Professor Raoult’s protocol is not tested stricto sensu in the Discovery trial?

As a reminder, the Raoult protocol is: hydroxychloroquine (200 mg x 3 per day for 10 days) + Azithromycin (500 mg on the 1st day then 250 mg per day for 5 more days)

the Raoult protocol made so much noise that the state was obliged to include it in its European discovery trial ….. but not its protocol


Didier Raoult (born March 13, 1952 in Dakar, Senegal) [1] is a French physician and microbiologist. He holds M.D. and Ph.D. degrees and specializes in infectious diseases. In 1984, Raoult created the Rickettsia Unit at Aix-Marseille University (AMU). He also teaches infectious diseases in the Faculty of Medicine of Aix-Marseille University, and since 1982 has supervised many M.D. and Ph.D. degrees. [2]

It is the only molecule which is no longer under patent of the protocol so they do not want it, but since it made a fuss, to calm everyone, they include chloroquine in the European test but not following the right protocol like that it will not work and they can say: well here you see we listened to you

Like that everyone happy.

They could not think that like you we are a lot because we are informed to have understood that the purpose of including chloroquine in the test is to discredit it.

It is exactly the same for the chloroquine restriction decree which authorizes its use for severe cases (by our French government) where the Raoult protocol highlights the low efficacy of chloroquine in severe cases!

there are over 30 clinical trials registered on clinicaltrialsdotgov right now for hydroxychloroquine. not just treating covid-19 infected but prophylactic treatment of health care professionals treating covid-19 patients. so doesn’t mean they are ethics approved. but wow.

Meanwhile, 3 big names in health-management in France support Raoult …

Dominique Maraninchi, Fabien Calvo and Jean-Luc Harousseau, former directors and presidents of the ANSM, the HAS and the INCA.

But they are saying Hydroxychloroquine-COVID-19 study did not meet publishing society’s “expected standard”:

If you are not working on the front line of this battle, consider registering here and see if your particular skill set can be utilized (COVID-19)

For my friends and colleagues ready to flex their scientific/medical skill sets against COVID-19, this maybe a good place to start 🙌🏻🦠🧬🔬💉🩺

For example, people are needed for the following tasks:

🦠Transcribe data from notebooks into tables

🦠Manual analysis of images (segmentation, tracking, identification of cells, etc.)

🦠Data curation and annotation

Examples of more complex tasks:

🧬Bioinformatic analysis

🧬Automated image analysis

🧬Finding a reagent you need

🧬Finding someone to train your team in a new protocol

🧬Finding an expert in a topic you need, and setting up an interview

🧬Doing a literature search on a topic unfamiliar to you

Crowdfight COVID-19

HBot is good for heart functions

A new study demonstrates the positive, sustained effect of hyperbaric oxygenation therapy (HBOT) protocols on heart function in healthy aging heart populations.

The study, led by Dr. Marina Leitman, Dr. Shmuel Fuchs, Dr. Amir Hadanny, Dr. Zvi Vered and Efrati, was published in the International Journal of Cardiovascular Imaging.